Meril Life Sciences comes late to aortic valves
The market for minimally invasive aortic implants is sewn up – can a tiny private group find a way in?
Diagnostics specialists win the US device approval race
The speediest device developer is Roche, but a look at companies’ strategies shows the perils of relying on bought-in tech.
Admedus moves from one unlikely area to another
A product sale nets the Australian company some much-needed cash, but its plan for the future is highly questionable.
TCT 2019 – Abbott's aortic valve disappoints
Portico hits noninferiority, but safety looks doubtful. Abbott might want to prioritise a different approach.
The extremes converge in big medtech’s hiring practices
Intuitive Surgical makes the most money per employee – but the title of “most improved” goes to Philips.
De novo device clearances fall out of fashion
The overall rate of device approvals in 2019 is holding steady on last year – but the types of approvals are different.
Big device deals are back in fashion
The medtech market’s fast growth and unfettered demand attracts investment groups, while hospital suppliers consolidate.
FDA adcom to pronounce on paclitaxel-coated devices
The recent disappointing sales of drug-coated devices for peripheral arterial disease look likely to become the norm.
Boston buys Vertiflex without investing first
A poor quarter is followed by an acquisition, but is it big enough?
